All Updates

All Updates

icon
Filter
M&A
Exscientia acquires full rights to CDK7 inhibitor programme for USD 20 million from GT Apeiron
AI Drug Discovery
Jul 18, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Jul 18, 2024

Exscientia acquires full rights to CDK7 inhibitor programme for USD 20 million from GT Apeiron

M&A

  • UK-based AI drug discovery company Exscientia has penned a licensing agreement with AI-powered biopharmaceutical company GT Apeiron for its oral CDK7 inhibitor program, GTAEXS617 ('617). The company will pay USD 10 million in upfront cash, USD 10 million in upfront equity, and potential single-digit royalty payments upon the drug's commercialization.

  • As per the agreement, Exscientia will gain full rights to the intellectual property and full control of the CDK7 inhibitor program. This oral CDK7 inhibitor, currently in its monotherapy dose escalation phase, is being evaluated in the ELUCIDATE clinical trial for its impact on advanced solid tumors. Subsequently, in late 2024 or early 2025, the trial will shift focus to breast cancer patients, specifically HR+/HER2 cases who have progressed on CDK4/6 inhibitors.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.